0.68
-0.021(-3.00%)
Currency In USD
| Previous Close | 0.7 |
| Open | 0.71 |
| Day High | 0.73 |
| Day Low | 0.63 |
| 52-Week High | 10.2 |
| 52-Week Low | 0.63 |
| Volume | 245,102 |
| Average Volume | 2.63M |
| Market Cap | 1.23M |
| PE | 0 |
| EPS | 164.37 |
| Moving Average 50 Days | 1.53 |
| Moving Average 200 Days | 1.89 |
| Change | -0.02 |
If you invested $1000 in Bluejay Diagnostics, Inc. (BJDX) since IPO date, it would be worth $0.02 as of December 30, 2025 at a share price of $0.679. Whereas If you bought $1000 worth of Bluejay Diagnostics, Inc. (BJDX) shares 3 years ago, it would be worth $0.22 as of December 30, 2025 at a share price of $0.679.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Bluejay Diagnostics Announces Completion of Commercial-Scale IL-6 Antibody Production
GlobeNewswire Inc.
Yesterday at 12:00 PM GMT
ACTON, Mass., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”) announced that it has completed commercial-scale production of both polyclonal and monoclonal antibodies targeting interleukin-6 (
Bluejay Diagnostics Corporate Update: Advancing Clinical Milestones and Strategic Partnerships
GlobeNewswire Inc.
Nov 10, 2025 12:30 PM GMT
Company focused on advancing clinical milestones and strategic partnerships, with goal of positioning itself for future FDA clearance and product commercialization.Patient enrollment in SYMON-II clinical trial now approximately 50% completed.Recent p
Bluejay Diagnostics Announces Closing of $4.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
GlobeNewswire Inc.
Oct 10, 2025 9:16 PM GMT
ACTON, Mass., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing near-patient solutions for critical care, today announced the closing of its previously